CLBIO Stock Overview
Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Corline Biomedical AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 12.65 |
| 52 Week High | SEK 17.80 |
| 52 Week Low | SEK 9.64 |
| Beta | 0.47 |
| 11 Month Change | -0.39% |
| 3 Month Change | 25.87% |
| 1 Year Change | -23.10% |
| 33 Year Change | -20.94% |
| 5 Year Change | -27.71% |
| Change since IPO | 23.41% |
Recent News & Updates
Recent updates
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth
Mar 15
We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow
Nov 26Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Jun 22We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth
Feb 16Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth
Jun 14Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation
Feb 28Shareholder Returns
| CLBIO | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 0.8% | -5.3% | -6.7% |
| 1Y | -23.1% | 70.7% | 9.9% |
Return vs Industry: CLBIO underperformed the Swedish Pharmaceuticals industry which returned 74.8% over the past year.
Return vs Market: CLBIO underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
| CLBIO volatility | |
|---|---|
| CLBIO Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: CLBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: CLBIO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 13 | Henrik Nittmar | www.corline.se |
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries.
Corline Biomedical AB Fundamentals Summary
| CLBIO fundamental statistics | |
|---|---|
| Market cap | SEK 271.86m |
| Earnings (TTM) | -SEK 4.50m |
| Revenue (TTM) | SEK 30.89m |
8.8x
P/S Ratio-60.5x
P/E RatioIs CLBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLBIO income statement (TTM) | |
|---|---|
| Revenue | SEK 30.89m |
| Cost of Revenue | SEK 6.10m |
| Gross Profit | SEK 24.79m |
| Other Expenses | SEK 29.28m |
| Earnings | -SEK 4.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 80.24% |
| Net Profit Margin | -14.56% |
| Debt/Equity Ratio | 0% |
How did CLBIO perform over the long term?
See historical performance and comparison